Fineline Cube

Follow:
14447 Articles
Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary's Resignation
Policy / Regulatory

Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation

CompanyDrug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

CompanyDrug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Company

Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division

CompanyDrug

Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain

CompanyDrug

CSPC Pharmaceutical’s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First‑Line Advanced Breast Cancer – HER2 Bispecific Combo Advances in China

CompanyDeals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

CompanyDrug

Betta Pharmaceuticals Partner EyePoint Reports EYP‑1901 Misses Primary Endpoint in First Pivotal Phase III LUGANO Trial for Wet AMD – DURAVYU Fails Non‑Inferiority vs. Aflibercept

CompanyDeals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP's TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
CompanyDrug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
CompanyDeals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

CompanyDrug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors